By Mrs. BullBear:
On Monday, September 15, 2014 TG Therapeutics Inc. (NASDAQ:TGTX) announced that they had reached an agreement with the FDA on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101, its...
TG Therapeutics, Inc. (Nasdaq: TGTX) announced today that it has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis approach of a...
By Tal Davidson:
Throughout my investing life, I have discovered that companies experiencing short term problems, yet favorable long term trends, and their management is honest and committed, urn out to be lucrative investment opportunities. These...
By Marshall Hargrave:
Tredegar (NYSE:TG) posted Q2 earnings of $0.11, or $0.34 per share (excluding special items). The company lacks analyst coverage, and had no consensus estimate for the quarter. Revenues were down 7.7% y/y. Its operating...
Q2 2014 Earnings Call
August 08, 2014 8:30 am ET
Neill Bellamy -
Nancy M. Taylor - Chief Executive Officer, President and Director
Kevin A. O'Leary - Chief Financial Officer, Vice President and...
TG Therapeutics, Inc. (NASDAQ:TGTX)
Q2 2014 Earnings Conference Call
July 22, 2014 08:30 AM ET
Jenna Bosco - Director, IR
Sean Power - CFO
Mike Weiss - Interim CEO
Joe Pantginis - ROTH Capital Partners
In a report published Wednesday, MLV & Co. analyst Graig C. Suvannavejh reiterated a Buy rating on TG Therapeutics (NASDAQ: TGTX), and raised the price target from $10.00 to $16.00.
In the report, MLV & Co noted, “We now raise our PT on TGTX...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.